Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Ab&B Bio-Tech CO., LTD. JS Class H ( (HK:2627) ) has provided an announcement.
Ab&B Bio-Tech CO., LTD. JS announced the approval of its quadrivalent subunit influenza vaccine by the National Medical Products Administration of China. This vaccine, the first of its kind approved in China for all age groups at full dosage, offers comprehensive protection with high antigen purity and low risk of adverse reactions. The approval marks a significant advancement for the company, potentially strengthening its market position and expanding its product offerings in the vaccine industry.
More about Ab&B Bio-Tech CO., LTD. JS Class H
Ab&B Bio-Tech CO., LTD. JS is a China-based vaccine company focused on the research, development, manufacturing, and commercialization of innovative and traditional vaccines using new technical methods. The company aims to replace traditional and imported vaccines in China and expand its presence internationally, with a product range that includes the quadrivalent subunit influenza vaccine and a lyophilized human rabies vaccine candidate.
Average Trading Volume: 1,791,672
See more insights into 2627 stock on TipRanks’ Stock Analysis page.